Resource use and risk factors in high-cost exacerbations of COPD.

[1]  J. V. van Noord,et al.  One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease , 2004, European Respiratory Journal.

[2]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[3]  E. Rönmark,et al.  The costs of exacerbations in chronic obstructive pulmonary disease (COPD). , 2002, Respiratory medicine.

[4]  Ramon Gisbert,et al.  Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. , 2002, Chest.

[5]  Toru Oga,et al.  Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. , 2002, Chest.

[6]  J. V. van Noord,et al.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.

[7]  M P Rutten-van Mölken,et al.  The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. , 2001, American journal of respiratory and critical care medicine.

[8]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[9]  J. Lorenz,et al.  [Socioeconomic relevance of acute exacerbations of chronic bronchitis in the Federal Republic of Germany. A prospective cost of illness study]. , 2001, Deutsche medizinische Wochenschrift.

[10]  S. Ramsey,et al.  The economic burden of COPD. , 2000, Chest.

[11]  M. Malesker,et al.  Pharmacoeconomic evaluation of COPD. , 2000, Chest.

[12]  T. Seemungal,et al.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[13]  B. Lindgren,et al.  The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. , 2000, Respiratory medicine.

[14]  J C Jager,et al.  Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. , 1999, Respiratory medicine.

[15]  Murray D. Altose,et al.  Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. , 1999, American journal of respiratory and critical care medicine.

[16]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[17]  J. G. Douglas,et al.  Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. , 1997, Thorax.

[18]  F. Fagnani,et al.  [Recurrent respiratory infections in patients with chronic obstructive bronchitis: medical treatment and costs]. , 1996, Revue des maladies respiratoires.

[19]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.